Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > Targretin (bexarotene)

Targretin (bexarotene) : Ligand Pharmaceuticals : Retinoid

Emerging Role of Rexinoids in NSCLC: Focus on Bexarotene (The Oncologist)
Explains the rationale for using rexinoids to treat cancer. Reviews past and current studies of bexarotene (Targretin) for the treatment of NSCLC. Concludes that Targretin shows promise for the treatment of NSCLC, citing the survival benefit demonstrated in early studies as well as the generally acceptable level of toxicity - specific known side effects are discussed. Notes that results from the ongoing Phase III trials will elucidate the role of Targretin in the treatment of NSCLC. [1/05]

SPIRIT I & II Pivotal Studies of Targretin IN NSCLC (Ligand Pharmaceuticals)
Manufacturer's press release provides update and answers to frequently asked questions on the status of SPIRIT I & SPIRIT II, two Phase III studies of Targretin (bexarotene) capsules in front-line combination therapy to treat advanced NSCLC. [1/05]

Targretin (bexarotene) - Recent MEDLINE Abstracts


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor